CILOSTAZOL FOR TREATMENT OF PATIENTS WITH DIABETIC LEG ULCERS

Ihor Kobza, Ivan Terletskyi

Abstract


Aim. The research was conducted for the purpose of improving treatment outcomes, reducing time on treatment, declining in disability, improving life quality of patient with diabetic ulcers.

Methods. In this research two groups of patients with diabetic leg ulcers were used: I group (51 patients) – treated with a standard procedure (control group) and second group (52 patients) – whether treatment was supplemented cytostazol (100 mg twice a day). For the evaluation the life quality of patients a questionnaire «SF - 36 Health Status Survey» was used during the treatment, the rate of the wound healing was calculated by the formula and 120 histological preparations were analyzed (20 patients of each group).

Results. After analysing the questionnaire results, significant differences were observed between groups of patients, manifested by de-emphasized role of physical problems, improved viability and psycho-emotional state with less manifestation of the differences in the control group. The reliable increase in the rate of wound healing was found in patients who took cilostazol. It was observed appearance of carbohydrate determinants in the endothelium of newly formed blood vessels after two weeks of treatment while in the most of the patients’ drugs of the control group there were no such obvious manifestations of regeneration.

Discussion. Regarding the results of the research, cilostazol is worth to be examined as perspective means for treatment of patients with diabetic ulcers. In turn, the results of lectinohistochemicals researches can be one of the objective tests of violation of balance of restorative-reparatory and destructively-necrotizing processes for patients with leg ulcers.


Keywords


trophic; chronic; leg; ulcer; wound; healing; regeneration; diabetic; cilostazol; lectines

Full Text:

PDF

References


Naves, C. C. L. M. (2016). The Diabetic Foot: A Historical Overview and Gaps in Current Treatment. Advances in Wound Care, 5 (5), 191–197. doi: 10.1089/wound.2013.0518

Chammas, N. K., Hill, R. L. R., Edmonds, M. E. (2016). Increased Mortality in Diabetic Foot Ulcer Patients: The Significance of Ulcer Type. Journal of Diabetes Research, 2016, 1–7. doi: 10.1155/2016/2879809

Game, F. L., Apelqvist, J., Attinger, C., Hartemann, A., Hinchliffe, R. J. et. al. (2016). Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review. Diabetes/Metabolism Research and Reviews, 32 (1), 154–168. doi: 10.1002/dmrr.2707

Bedenis, R., Stewart, M., Cleanthis, M., Robless, P., Mikhailidis, D. P., Stansby, G. (2014). Cilostazol for intermittent claudication. Cochrane Database of Systematic Reviews. doi: 10.1002/14651858.cd003748.pub4

Kobza, I. I., Terletskiy, I. R., Verhola, M. R., Savchenko, A. A., Vykhtyuk, T. I. (2016). Likuvannia patsiientiv z khronichnymy vyrazkamy nyzhnikh kintsivok [Treatment of patients with trophic ulcers of the lower extremities]. Klinichna flebolohiia [Clinical phlebology], 9 (1), 43–47.

Kobza, I. I., Terletskiy, I. R., Verhola, M. R., Savchenko, A. A., Vykhtyuk, T. I. (2016). Rezultaty likuvannia patsiientiv z trofichnymy vyrazkamy nih [Results of treatment of patients with trophic ulcers of the leg]. Halytskyi likarskyi visnyk [Galician Medical Journal], 23 (3), 11–14.

De Franciscis, S., Gallelli, L., Battaglia, L., Molinari, V., Montemurro, R., Stillitano, D. M. et. al. (2015). Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease. International Wound Journal, 12 (3), 250–253. doi: 10.1111/iwj.12085

Wada, T., Onogi, Y., Kimura, Y., Nakano, T., Fusanobori, H., Ishii, Y. et. al. (2013). Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions. European Journal of Pharmacology, 707 (1-3), 120–129. doi: 10.1016/j.ejphar.2013.03.016

Spear, M. (2013). Acute or Chronic? Whatʼs the Difference? Plastic Surgical Nursing, 33 (2), 98–100. doi: 10.1097/psn.0b013e3182965e94

Svyrydov, M. V. (2008). Innovatsiini pidkhody do zahoiennia obshyrnykh ranovykh defektiv stop u khirurhii piznikh uskladnen u khvorykh iz syndromom diabetychnoi stopy [Innovative approaches to the healing of extensive wound defect of feet in the surgery of late complications in patients with diabetic foot syndrome]. Klinichna endokrynolohiia ta endokrynna khirurhiia [Clinical endocrinology and endocrine surgery], 4 (25), 10–14.

Ware, J. E. (2000). SF-36 Health Survey Update. Spine, 25 (24), 3130–3139. doi: 10.1097/00007632-200012150-00008

Preima, Kh. I., Yashchenko, A. M. (2009). Rol hlikokoniuhativ u protsesakh morfohenezu shkiry potomstva na tli hipotyreozu materynskoho orhanizmu [Role of glycoconjugates in the processes of skin morphogenesis in the offspring with underlying maternal organism’s hypothyrosis]. Bukovynskyi medychnyi visnyk [Bukovinian Medical Herald Journal], 13 (4), 232–236.

Yashchenko, A. M., Pankevych, L. V., Lutsyk, A. D. (2012). Rat liver carbohydrate alterations in streptozotocin-induced diabetic rats. European Journal of Anatomy, 16 (2), 82–90.




DOI: http://dx.doi.org/10.21303/2585-663.2017.00458

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Ihor Kobza, Ivan Terletskyi

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2585-6634 (Online), ISSN 2585-6626 (Print)